Upbeat study results for Alnylam Pharmaceuticals

Arbutus Biopharma Corp.'s (Nasdaq: ABUS) licensee Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY) reported upbeat APOLLO Phase 3 study results of patisiran, which is enabled by Arbutus's lipid nanoparticle technology. Shares of Arbutus Biopharma climbed $1.15 to close at $6.70 while Alnylam Pharmaceuticals stock rocketed $38.80 to close at $113.84.